Embryofetal Development Study of Vismodegib, a Hedgehog Pathway Inhibitor, in Rats
Authors:
- 1 April 2014
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 101 (2) , 135-143
Abstract
Vismodegib (Erivedge) is a first-in-class small-molecule hedgehog pathway inhibitor for the treatment of adults with advanced basal-cell carcinoma. Because this pathway is known to play key roles in patterning and growth during vertebrate development, vismodegib was anticipated to be embryotoxic. To support marketing applications, an embryofetal development study was completed in which a limited number of pregnant rats (n = 6/group) was administered vismodegib by oral gavage on gestation days 6 to 17. When vismodegib was administered at ≥60 mg/kg/day, doses associated with evidence of pharmacologic activity in previous rat toxicity studies, all conceptuses were resorbed at an early embryonic stage in the absence of significant maternal toxicity. When administered at 10 mg/kg/day, corresponding to an exposure (AUC0–24h) approximately 15% of the median in patients at steady state, a variety of malformations were observed, including absent/fused digits in the hindlimb of multiple fetuses, multiple craniofacial abnormalities in one fetus, and an anorectal defect in one fetus. In addition, the incidence of variations, including dilated renal pelvis or ureter and incompletely or unossified skeletal elements, was significantly greater when compared with the controls. These results confirmed that vismodegib is likely to be embryotoxic at clinically relevant maternal exposures, and doses ≥60 mg/kg/day resulted in a 100% incidence of embryolethality that likely resulted from severe defects in early embryonic development. In contrast, craniofacial defects typically associated with hedgehog pathway inhibition were only observed in one fetus at the low dose of 10 mg/kg/day, which likely reflected minimal or intermittent pathway inhibition at low exposures.Keywords
This publication has 17 references indexed in Scilit:
- Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein BindingClinical Cancer Research, 2011
- Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitorXenobiotica, 2009
- Cell lineage analysis demonstrates an endodermal origin of the distal urethra and perineumDevelopmental Biology, 2008
- Dose- and Route-Dependent Teratogenicity, Toxicity, and Pharmacokinetic Profiles of the Hedgehog Signaling Antagonist Cyclopamine in the MouseToxicological Sciences, 2008
- Targeting the Hedgehog pathway in cancerNature Reviews Drug Discovery, 2006
- Anorectal Malformations Caused by Defects in Sonic Hedgehog SignalingThe American Journal of Pathology, 2001
- “Apparent hydronephrosis” as a normal aspect of renal development in late gestation of rats: The effect of methyl salicylateTeratology, 1972
- Congenital Deformities in Lambs, Calves, and Goats Resulting from Maternal Ingestion ofVeratrum californicum; Hare Lip, Cleft Palate, Ataxia, and Hypoplasia of Metacarpal and Metatarsal BonesClinical Toxicology, 1972
- A rapid method for detecting malformations in rat fetusesJournal of Morphology, 1969
- A Note on the Staining of the Skeleton of Cleared Specimens with Alizarin Red SStain Technology, 1926